Published in Protein Expr Purif on April 01, 2004
NFkappaB negatively regulates interferon-induced gene expression and anti-influenza activity. J Biol Chem (2006) 1.38
Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics. Biotechnol Adv (2011) 1.07
Bioinformatic analysis reveals cRel as a regulator of a subset of interferon-stimulated genes. J Interferon Cytokine Res (2008) 0.99
PEGylation of interleukin-10 for the mitigation of enhanced pain states. J Biomed Mater Res A (2010) 0.88
N-terminal protein modification using simple aminoacyl transferase substrates. J Am Chem Soc (2011) 0.86
PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J Biomed Mater Res A (2009) 0.85
PEGylated interferon-beta modulates the acute inflammatory response and recovery when combined with forced exercise following cervical spinal contusion injury. Exp Neurol (2010) 0.83
Specific modulation of protein activity by using a bioorthogonal reaction. Chembiochem (2014) 0.77
Population-Based Pharmacokinetic and Exposure-Efficacy Analyses of Peginterferon Beta-1a in Patients With Relapsing Multiple Sclerosis. J Clin Pharmacol (2017) 0.75
Unphosphorylated STAT3 regulates the antiproliferative, antiviral, and gene-inducing actions of type I interferons. Biochem Biophys Res Commun (2017) 0.75
Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell (2009) 6.54
Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol (2008) 6.38
Function of mitochondrial Stat3 in cellular respiration. Science (2009) 5.13
High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteomics (2007) 4.72
High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat Methods (2009) 4.17
Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity (2004) 4.00
Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol (2010) 3.67
Reproducible isolation of distinct, overlapping segments of the phosphoproteome. Nat Methods (2007) 3.46
Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring. Mol Cell Proteomics (2008) 3.29
LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci (2004) 3.24
A database of mass spectrometric assays for the yeast proteome. Nat Methods (2008) 3.19
The implications of proteolytic background for shotgun proteomics. Mol Cell Proteomics (2007) 2.82
LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci (2005) 2.61
TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron (2005) 2.39
Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics (2014) 2.37
An integrated, directed mass spectrometric approach for in-depth characterization of complex peptide mixtures. Mol Cell Proteomics (2008) 2.35
The human proteome project: current state and future direction. Mol Cell Proteomics (2011) 2.34
Multiple actions of systemic artemin in experimental neuropathy. Nat Med (2003) 2.12
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination. Nat Med (2011) 2.08
Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J Cell Biol (2007) 2.07
Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics (2012) 2.04
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med (2005) 1.92
Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe (2011) 1.86
Structure of human urokinase plasminogen activator in complex with its receptor. Science (2006) 1.84
Attenuated liver fibrosis in the absence of B cells. J Clin Invest (2005) 1.82
Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A (2008) 1.81
Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia. Circ Res (2012) 1.80
Selected reaction monitoring applied to proteomics. J Mass Spectrom (2011) 1.75
Increased selectivity, analytical precision, and throughput in targeted proteomics. Mol Cell Proteomics (2010) 1.71
Structural details and composition of Trichomonas vaginalis lipophosphoglycan in relevance to the epithelial immune function. Glycoconj J (2008) 1.69
Interferon-beta reduces proteinuria in experimental glomerulonephritis. J Am Soc Nephrol (2007) 1.63
Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology (2006) 1.61
Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol (2005) 1.57
Survey of enterovirus infections from hand, foot and mouth disease outbreak in China, 2009. Virol J (2011) 1.55
Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci (2006) 1.55
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci (2010) 1.53
Epitope-dependent effect of anti-murine TIM-1 monoclonal antibodies on T cell activity and lung immune responses. J Immunol (2007) 1.52
T cell, Ig domain, mucin domain-2 gene-deficient mice reveal a novel mechanism for the regulation of Th2 immune responses and airway inflammation. J Immunol (2006) 1.51
Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study. J Travel Med (2014) 1.49
Risk stratification by adenosine stress cardiac magnetic resonance in patients with coronary artery stenoses of intermediate angiographic severity. JACC Cardiovasc Imaging (2009) 1.49
Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. Blood (2011) 1.49
Simultaneous adrenal and extra-adrenal myelolipoma - an uncommon incident: case report and review of the literature. World J Surg Oncol (2008) 1.46
IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther (2008) 1.45
Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem (2006) 1.41
NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J Neurosci (2007) 1.39
Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site. Structure (2008) 1.39
Role of nuclear factor-kappaB in the antiviral action of interferon and interferon-regulated gene expression. J Biol Chem (2004) 1.38
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem (2006) 1.33
A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol (2011) 1.33
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet (2010) 1.32
Catheter ablation of atrial fibrillation using the Navx-/Ensite-system and a CT-/MRI-guided approach. Clin Res Cardiol (2009) 1.31
Current concepts in the classification, diagnosis and treatment of vascular anomalies. Eur J Radiol (2010) 1.30
Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol (2003) 1.30
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res (2011) 1.30
Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. PLoS One (2010) 1.29
LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury. Mol Cell Neurosci (2006) 1.28
Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest (2003) 1.27
Crystal structure of type IIE restriction endonuclease EcoRII reveals an autoinhibition mechanism by a novel effector-binding fold. J Mol Biol (2004) 1.26
SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol (2008) 1.26
Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site. J Mol Biol (2005) 1.25
Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol (2002) 1.23
Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry (2005) 1.23
Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells. J Biol Chem (2006) 1.23
Ligand-independent pathway that controls stability of interferon alpha receptor. Biochem Biophys Res Commun (2007) 1.21
Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci U S A (2009) 1.17
Multislice first-pass myocardial perfusion imaging: Comparison of saturation recovery (SR)-TrueFISP-two-dimensional (2D) and SR-TurboFLASH-2D pulse sequences. J Magn Reson Imaging (2004) 1.14
Growth factor induction of Cripto-1 shedding by glycosylphosphatidylinositol-phospholipase D and enhancement of endothelial cell migration. J Biol Chem (2007) 1.14
Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling. Mol Cell Biol (2009) 1.13
Protection against progressive leishmaniasis by IFN-beta. J Immunol (2004) 1.12
Perfusion MR imaging with FAIR true FISP spin labeling in patients with and without renal artery stenosis: initial experience. Radiology (2006) 1.11
Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b vs. IFN-beta 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J Interferon Cytokine Res (2002) 1.11
Long-acting forms of Sonic hedgehog with improved pharmacokinetic and pharmacodynamic properties are efficacious in a nerve injury model. J Pharm Sci (2002) 1.10
Quantitative proteomics and protein network analysis of hippocampal synapses of CaMKIIalpha mutant mice. J Proteome Res (2007) 1.10
Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs (2013) 1.10
Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol Cell Biol (2010) 1.10
Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor. J Biol Chem (2009) 1.09
Assessment of left ventricular myocardial function using 16-slice multidetector-row computed tomography: comparison with magnetic resonance imaging and echocardiography. Eur Radiol (2005) 1.07
A comprehensive approach to the analysis of contrast enhanced cardiac MR images. IEEE Trans Med Imaging (2008) 1.06
Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. Proc Natl Acad Sci U S A (2012) 1.03
Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation. Toxicol Sci (2011) 1.02
Bacillus megaterium strain XTBG34 promotes plant growth by producing 2-pentylfuran. J Microbiol (2010) 1.02
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res (2006) 1.01
Monitoring the transition from the T to the R state in E.coli aspartate transcarbamoylase by X-ray crystallography: crystal structures of the E50A mutant enzyme in four distinct allosteric states. J Mol Biol (2004) 1.01
Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla. Invest Radiol (2006) 1.00
Atherosclerotic disease: whole-body cardiovascular imaging with MR system with 32 receiver channels and total-body surface coil technology--initial clinical results. Radiology (2005) 0.99
Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transection. Invest Ophthalmol Vis Sci (2008) 0.99
Structure of an insect epsilon class glutathione S-transferase from the malaria vector Anopheles gambiae provides an explanation for the high DDT-detoxifying activity. J Struct Biol (2008) 0.99
Enterovirus coinfection during an outbreak of hand, foot, and mouth disease in Shandong, China. Clin Infect Dis (2011) 0.99
Basal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motif. J Biol Chem (2008) 0.99